Novartis and Unnatural Products sign cardiovascular deal worth up to 1.7 billion dollars
Unnatural Products signed a licensing deal with Novartis on Wednesday for cardiovascular therapies. The agreement is worth up to 1.7 billion dollars in total.
Insights:
Unnatural Products has signed a licensing agreement with Novartis AG to develop macrocyclic peptide-based therapies for a cardiovascular program in a deal announced today, February 18, 2026. The completed agreement is reported to be worth up to $1.7 billion and represents a substantial commercial and development commitment between the two companies.
The partnership focuses on the advancement of macrocyclic peptide-based therapies within the scope of a cardiovascular program. This agreement is material in scale and marks a significant company-level commitment for both Unnatural Products and Novartis. By signing this deal, the two parties have committed substantial financial and development resources to the program.
